Parameters | Controls | Patient groups | |
---|---|---|---|
 | (n = 15) | With chelation [Group I] (n = 34) | Without chelation [Group II] (n = 35) |
Cystatin-C (mg/L) | 0.83 ± 0.05 | 1.26 ± 0.34 | 1.03 ± 0.26 |
Range | (0.80 - 0.90) | (0.85-2.00) | (0.82-2.12) |
Significance | Â | P < 0.0001 | P < 0.022, * P < 0.001 |
Creatinine (mg/dL) | 0.55 ± 0.08 | 0.75 ± 0.18 | 0.70 ± 0.21 |
Range | (0.50 -0.70) | (0.50-1.10) | (0.40-1.10) |
Significance | Â | P < 0.001 | P < 0.008, *P < 0.262 |
eGFR Schwartz (mL/min/1.73 m2) | 119.08 ± 11.13 | 92.67 ± 25.16 | 93.73 ± 25.53 |
Range | (96.25-125.40) | (53.17-125.40) | (49.50-125.40) |
Significance | Â | P < 0.001 | P < 0.001, *P < 0.852 |
≥90 mL/minute/1.73 m2 | 15 (100.00%) | 14 (41.18%) | 19 (54.29%) |
< 90 mL/minute/1.73 m2 | Â | 20 (58.82%) | 16 (45.71%) |
Uric acid (mg/dL) | 3.81 ± 1.19 | 5.69 ± 1.69 | 5.30 ± 1.49 |
Range | (2.50-5.50) | (2.00-8.50) | (2.50-7.50) |
Significance | Â | P < 0.0001 | P < 0.002, *P < 0.292 |
Calcium (mg/dL) | 9.35 ± 1.11 | 9.10 ± 1.41 | 8.59 ± 1.86 |
Range | (8.01-10.95) | (6.09-11.10) | (5.35-12.37) |
Significance | Â | P < 0.121 | P < 0.607, *P < 0.183 |
Inorganic phosphate (mg/dL) | 3.32 ± 0.72 | 4.69 ± 0.87 | 4.50 ± 1.14 |
Range | (2.38-4.40) | (3.60-7.11) | (2.31-6.92) |
Significance | Â | P < 0.001 | P < 0.001, *P < 0.412 |
Total antioxidant capacity (mmol/L) | 0.43 ± 0.12 | 0.18 ± 0.10 | 0.23 ± 0.13 |
Range | (0.24-0.60) | (0.03-0.36) | (0.02-0.41) |
Significance | Â | P < 0.0001 | P < 0.0001, * P < 0.048 |